WO2026012523 - SODIUM CHANNEL MODULATOR
National phase entry is expected:
Publication Number
WO/2026/012523
Publication Date
15.01.2026
International Application No.
PCT/CN2025/120227
International Filing Date
10.09.2025
Title **
[English]
SODIUM CHANNEL MODULATOR
[French]
MODULATEUR DE CANAL SODIQUE
[Chinese]
钠通道调节剂
Applicants **
ALICORN PHARMACEUTICAL CO., LTD
Inventors
LU, Pingbo
ZHU, Hui
DONG, Siqi
LIU, Xing
YU, Chengfeng
ZHOU, Dongli
Priority Data
202410935004.2
11.07.2024
CN
202410961869.6
17.07.2024
CN
202411237584.4
04.09.2024
CN
202411449827.0
16.10.2024
CN
202411666485.8
20.11.2024
CN
202510286388.4
11.03.2025
CN
202510502386.4
21.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2284 | |
| EPO | Filing, Examination, Granting | 12747 | |
| Japan | Filing, Examination, Granting | 2186 | |
| South Korea | Filing, Examination, Granting | 2401 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,358
Contact Us
Abstract[English]
Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).[French]
La présente invention concerne un composé tel que représenté par la formule I qui peut être utilisé en tant que modulateur de canal sodique et un stéréoisomère, tautomère ou sel pharmaceutiquement acceptable de celui-ci. L'invention concerne en outre une composition pharmaceutique contenant le composé et le stéréoisomère, tautomère, ou sel pharmaceutiquement acceptable de celui-ci, et un véhicule ou un excipient, et son utilisation pharmaceutique en tant qu'inhibiteur de NaV1.8 (contre, par exemple, la douleur, les maladies respiratoires, les troubles neurologiques et les maladies mentales).[Chinese]
本发明提供了一种可用作钠通道调剂剂的如式I所示的化合物及其立体异构体、互变异构体或其药学可接受的盐，还提供了包含所述化合物及其立体异构体、互变异构体或其药学可接受的盐和载体或赋形剂的药物组合物及其作为NaV1.8抑制剂的药物用途(比如疼痛、呼吸道疾病、神经紊乱和精神疾病等)。